Patients with specific TIME subtype and ALK fusion mutations (confirmed via RNA-seq and OncoKB annotation) will receive tyrosine kinase inhibitors (TKIs, e.g., alectinib or crizotinib) as first-line: clinical trials recruiting now
Fewer than 3 recruiting trials found.
1
Recruiting trials
2
Conditions studied
0
US states with sites
1
Countries
Phase breakdown
Not applicable 1
Conditions being studied
| Condition | Trials |
|---|---|
| Lung cancer | 1 |
| Signet Ring Cell Carcinoma of the Lung | 1 |
Recruiting trials involving Patients with specific TIME subtype and ALK fusion mutations (confirmed via RNA-seq and OncoKB annotation) will receive tyrosine kinase inhibitors (TKIs, e.g., alectinib or crizotinib) as first-line
Common questions
How many recruiting trials involve Patients with specific TIME subtype and ALK fusion mutations (confirmed via RNA-seq and OncoKB annotation) will receive tyrosine kinase inhibitors (TKIs, e.g., alectinib or crizotinib) as first-line?
1 recruiting trial across 2 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.